Lifestyle
- Regular aerobic exercise
- Weight management
- Smoking cessation
Low-Density Lipoprotein · LDL-C · LDL
LDL-C quantifies the amount of cholesterol carried by low-density lipoproteins in the blood.
Fasting is required for accurate measurement. Reference ranges may vary slightly based on laboratory standards.
Low-Density Lipoprotein Cholesterol (LDL-C) is a type of lipoprotein responsible for transporting cholesterol to cells throughout the body. It is often referred to as 'bad cholesterol' due to its association with an increased risk of atherosclerosis, where cholesterol deposits form plaques in arterial walls, potentially leading to cardiovascular diseases. Clinically, LDL-C is a critical marker for assessing cardiovascular risk. Elevated levels are linked to a higher incidence of major adverse cardiovascular events (MACEs), such as heart attacks and strokes. Researchers have found that LDL-C, along with other biomarkers like lipoprotein(a) and high-sensitivity C-reactive protein, independently predicts cardiovascular events. For athletes and biohackers, maintaining optimal LDL-C levels is crucial for cardiovascular health and longevity. Lower LDL-C levels are generally associated with reduced risk of cardiovascular diseases, which can enhance overall health and performance. However, even with well-regulated LDL-C, residual cardiovascular risk may persist due to other lipid imbalances. Caveats in LDL-C measurement include the need for fasting samples to ensure accuracy, as recent food intake can alter lipid levels. Additionally, factors such as genetic predispositions, medications, and lifestyle can influence LDL-C levels, necessitating a comprehensive approach to interpretation.
Klinische Bedeutung
Elevated LDL-C levels indicate an increased risk for atherosclerosis and cardiovascular diseases. Lower levels are generally associated with a reduced risk of these conditions.
Progressively rising LDL-C values suggest an increased risk of cardiovascular disease. Re-test in 4-6 weeks if levels are outside the optimal range.
Falling LDL-C values may indicate improved cardiovascular risk profile, often due to lifestyle or medication changes.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if on cholesterol-lowering medications.
Testing Frequency
Annually for healthy adults, more frequently if at risk for cardiovascular disease.
Directly measures
Current research suggests that the optimal target levels for LDL-C in different populations, particularly those with elevated lipoprotein(a), remain debated, as well as the influence of confounders like inflammation and medication use on cardiovascular risk. Emerging research directions include the evaluation of LDL-C corrected for Lp(a) content as a more accurate risk marker. However, clinical questions remain unanswered regarding the long-term implications of LDL-C and Lp(a) interactions on cardiovascular outcomes in diverse patient cohorts.
816
Total Citations
10
Human/RCT
6.3
Avg. Influence
2025
Latest
This review discussed the triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a potential biomarker for predicting metabolic syndrome and cardiovascular disease. Researchers highlighted that even when LDL-C levels are well managed, residual risks for cardiovascular disease persist due to other lipid disturbances. The TG/HDL-C ratio may serve as a valuable predictor for these conditions.
This review examined the significance of apolipoprotein B (apoB) as a biomarker for cardiovascular disease. Researchers found that apoB levels provide a more accurate measure of atherogenic lipoproteins compared to low-density lipoprotein cholesterol (LDL-C). The review discusses the ongoing debate regarding the use of apoB in clinical guidelines for cardiovascular risk assessment.
This systematic review and meta-analysis evaluated blood biomarkers related to post-stroke cognitive impairment (PSCI). Researchers found that levels of homocysteine, C-reactive protein, total cholesterol, and low-density lipoprotein cholesterol (LDL-C) were significantly higher in patients with PSCI compared to those without. The study suggests these biomarkers could be useful in identifying patients at risk for cognitive decline after a stroke.
This study explored the role of second-generation obesity medications in managing obesity as a chronic disease. Researchers noted that effective weight loss achieved with these medications can improve health outcomes and reduce complications associated with obesity. LDL-C was highlighted as a key biomarker for monitoring treatment effectiveness and guiding therapy.
This study investigated the relationship between low-density lipoprotein cholesterol (LDL-C) levels and bone mineral density (BMD) in adults aged 20 to 59. Researchers found a negative association between LDL-C and lumbar BMD, indicating that higher LDL-C levels may be linked to lower bone density. The study suggests that LDL-C could serve as a biomarker for early osteoporosis detection.
This study examined the effects of pelacarsen on low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) cholesterol (Lp(a)-C) in patients with cardiovascular disease. Researchers found that pelacarsen significantly reduced Lp(a)-C levels and had a mild effect on LDL-C corrected for Lp(a)-C content. The study suggests that LDL-C corrected provides a more accurate reflection of changes in LDL-C than laboratory-reported LDL-C.
This narrative review examined the relationship between hypothyroidism and lipid abnormalities, particularly focusing on LDL-C levels. Researchers found that higher thyroid-stimulating hormone (TSH) levels were associated with increased LDL-C, and thyroid hormone treatment effectively reversed these lipid abnormalities. The findings suggest that hypothyroidism may be an important factor in managing cardiovascular risk.
This review focused on recombinant high-density lipoprotein formulations as potential therapies for cardiovascular disease. Researchers noted that low-density lipoprotein cholesterol (LDL-C) lowering therapies have limited effectiveness in raising HDL-C levels. The study emphasizes the need for further clinical trials to evaluate the efficacy of novel HDL-modifying therapies.
This review highlighted the clinical significance of electronegative low-density lipoprotein (L5 LDL) cholesterol in atherothrombosis. Researchers noted that elevated L5 LDL levels correlate with the severity of cardiovascular diseases and may serve as a promising biomarker for assessing cardiovascular risk. The study emphasizes the need for further research to develop effective strategies for lowering L5 LDL levels.
This review focused on the relationship between lipoprotein(a) [Lp(a)], low-density lipoprotein cholesterol (LDL-C), and familial hypercholesterolemia (FH). Researchers found that Lp(a) and LDL-C are both significant risk factors for cardiovascular disease in FH individuals. The study emphasizes the need for careful management of Lp(a) levels in this population.
Research publications about LDL-Cholesterin over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer